Other News To Note
• Amarin Corp. plc, of Dublin, Ireland, said it was notified by the FDA that no advisory meeting will be scheduled in connection with the new drug application for AMR101 (icosapent ethyl), a prescription-grade omega-3 fatty acid, for use in patients with very high triglycerides (less than or equal to 500 mg/dL). The agency has set a PDUFA date of July 26.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST